Solid Lipid Nanoparticles

Oral administration of biologics such as peptides, proteins, vaccines, and nucleic acids is one of the most significant challenges because of enzymatic breakdown, acidic gastric environment, and low absorption in the intestines. Polymeric nanoparticle has become a potential solution to surmount these obstacles, as it provides protection of biologics, controlled release as well as increased mucosal uptake. This review will present a pharmaceutics-oriented overview of recent developments in polymeric nanoparticle-based oral delivery systems with particular emphasis on preclinical animal studies. The significant advances in natural and synthetic polymers, surface modification techniques including mucoadhesion, conjugation of ligands and pH- sensitive coatings and the applications in different classes of biologics are also critically examined. The animal studies show enhanced oral bioavailability, prolonged therapeutic effect and improved immune response, showing the potential of the systems as less invasive methods of administration compared to the conventional administration. Although some of these advances have been made, issues of formulation complexity, reproducibility, large-scale production and long-term safety have yet to be resolved. This review highlights the existing gaps and suggests future research to enable translation of polymeric nanoparticles in oral biologic delivery into clinical practice.

Non-steroidal anti-inflammatory drugs (NSAIDs) have wide applicability in management of inflammatory and pain related diseases but limited applicability is characterized by common use and gastrointestinal disturbance. Present study is the trying to come up with sustained release (SR) matrix tablets of NSAIDs using hydrophilic and hydrophobic polymers and correlate the results of in-vitro drug release with the in-vivo pharmacokinetics response. The Ibuprofen drug was selected to be the model, and the direct compression of matrix tablet with HPMC K100M and ethyl cellulose was done. The drug was undergone in-vitro dissolution study using USP-II apparatus with phosphate buffer (pH7.2) and during in-vivo pharmacokinetics testing using healthy volunteers approach crossover study. They came up with a favourable Level An in-vitro/ in-vivo correlation (IVIVC) (R 2= 0.987), showing that the in-vitro kinetics of drug released is a fair representation of the average put on plasma. Sustained release matrix has succeeded in prolonging the duration of drug release to 12 hours and reduced Cmax which contributed to reduction of adverse effects related to a peak. These findings encourage studies into establishing the means of developing SR NSAID formulation to assist in GI toxicity and compliance in patients.